Robert “Bob” Campbell

Robert “Bob” Campbell, Ph.D., is currently the Chief Scientific Officer at Grove Biopharma, Inc., where they lead the development of the Bionic Biologics platform aimed at improving treatments for cancer, neurodegenerative diseases, and rare disorders. With over 35 years of experience in drug discovery across both biotech and large pharmaceutical companies, they have contributed significantly to the field, including the advancement of Eli Lilly's kinase platform that led to the approval of Verzenio in 2017. They have held various leadership roles, including directing the Oncology division at the Lilly Singapore Centre for Drug Discovery, and have authored more than 130 publications. In addition to their scientific achievements, they serve as Editor-in-Chief of SLAS Discovery and contribute to drum-related publications as a talented drummer.